BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 34012068)

  • 1. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT; Lee K; Chung WK; Gordon AS; Herman GE; Klein TE; Stewart DR; Amendola LM; Adelman K; Bale SJ; Gollob MH; Harrison SM; Hershberger RE; McKelvey K; Richards CS; Vlangos CN; Watson MS; Martin CL;
    Genet Med; 2021 Aug; 23(8):1381-1390. PubMed ID: 34012068
    [No Abstract]   [Full Text] [Related]  

  • 2. ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT; Lee K; Abul-Husn NS; Amendola LM; Brothers K; Chung WK; Gollob MH; Gordon AS; Harrison SM; Hershberger RE; Klein TE; Richards CS; Stewart DR; Martin CL;
    Genet Med; 2022 Jul; 24(7):1407-1414. PubMed ID: 35802134
    [No Abstract]   [Full Text] [Related]  

  • 3. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT; Lee K; Abul-Husn NS; Amendola LM; Brothers K; Chung WK; Gollob MH; Gordon AS; Harrison SM; Hershberger RE; Klein TE; Richards CS; Stewart DR; Martin CL;
    Genet Med; 2023 Aug; 25(8):100866. PubMed ID: 37347242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correspondence on "ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)" by Miller et al.
    McGurk KA; Zheng SL; Henry A; Josephs K; Edwards M; de Marvao A; Whiffin N; Roberts A; Lumbers TR; O'Regan DP; Ware JS
    Genet Med; 2022 Mar; 24(3):744-746. PubMed ID: 34906520
    [No Abstract]   [Full Text] [Related]  

  • 5. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT; Lee K; Gordon AS; Amendola LM; Adelman K; Bale SJ; Chung WK; Gollob MH; Harrison SM; Herman GE; Hershberger RE; Klein TE; McKelvey K; Richards CS; Vlangos CN; Stewart DR; Watson MS; Martin CL;
    Genet Med; 2021 Aug; 23(8):1391-1398. PubMed ID: 34012069
    [No Abstract]   [Full Text] [Related]  

  • 6. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
    Kalia SS; Adelman K; Bale SJ; Chung WK; Eng C; Evans JP; Herman GE; Hufnagel SB; Klein TE; Korf BR; McKelvey KD; Ormond KE; Richards CS; Vlangos CN; Watson M; Martin CL; Miller DT
    Genet Med; 2017 Feb; 19(2):249-255. PubMed ID: 27854360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
    ACMG Board of Directors
    Genet Med; 2019 Jul; 21(7):1467-1468. PubMed ID: 31019278
    [No Abstract]   [Full Text] [Related]  

  • 8. Correction to: ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT; Lee K; Chung WK; Gordon AS; Herman GE; Klein TE; Stewart DR; Amendola LM; Adelman K; Bale SJ; Gollob MH; Harrison SM; Hershberger RE; McKelvey K; Richards CS; Vlangos CN; Watson MS; Martin CL;
    Genet Med; 2021 Aug; 23(8):1582-1584. PubMed ID: 34345026
    [No Abstract]   [Full Text] [Related]  

  • 9. The ACMG SF v3.0 gene list increases returnable variant detection by 22% when compared with v2.0 in the ClinSeq cohort.
    Johnston JJ; Brennan ML; Radenbaugh B; Yoo SJ; Hernandez SM; ; Lewis KL; Katz AE; Manolio TA; Biesecker LG
    Genet Med; 2022 Mar; 24(3):736-743. PubMed ID: 34906458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of fetal exome sequencing in prenatal diagnosis: a points to consider document of the American College of Medical Genetics and Genomics (ACMG).
    Monaghan KG; Leach NT; Pekarek D; Prasad P; Rose NC;
    Genet Med; 2020 Apr; 22(4):675-680. PubMed ID: 31911674
    [No Abstract]   [Full Text] [Related]  

  • 11. Copy number alterations involving 59 ACMG-recommended secondary findings genes.
    Yatsenko SA; Aarabi M; Hu J; Surti U; Ortiz D; Madan-Khetarpal S; Saller DN; Bellissimo D; Rajkovic A
    Clin Genet; 2020 Dec; 98(6):577-588. PubMed ID: 33009833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
    Green RC; Berg JS; Grody WW; Kalia SS; Korf BR; Martin CL; McGuire AL; Nussbaum RL; O'Daniel JM; Ormond KE; Rehm HL; Watson MS; Williams MS; Biesecker LG;
    Genet Med; 2013 Jul; 15(7):565-74. PubMed ID: 23788249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Points to consider in the practice of postmortem genetic testing: A statement of the American College of Medical Genetics and Genomics (ACMG).
    Deignan JL; De Castro M; Horner VL; Johnston T; Macaya D; Maleszewski JJ; Reddi HV; Tayeh MK;
    Genet Med; 2023 May; 25(5):100017. PubMed ID: 36799919
    [No Abstract]   [Full Text] [Related]  

  • 14. Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).
    Li MM; Chao E; Esplin ED; Miller DT; Nathanson KL; Plon SE; Scheuner MT; Stewart DR;
    Genet Med; 2020 Jul; 22(7):1142-1148. PubMed ID: 32321997
    [No Abstract]   [Full Text] [Related]  

  • 15. Stewardship of patient genomic data: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Best RG; Khushf G; Rabin-Havt SS; Clayton EW; Grebe TA; Hagenkord J; Topper S; Fivecoat J; Chen M; Grody WW;
    Genet Med; 2022 Mar; 24(3):509-511. PubMed ID: 35253644
    [No Abstract]   [Full Text] [Related]  

  • 16. The rate of secondary genomic findings in the Saudi population.
    Aloraini T; Alsubaie L; Alasker S; Al Muitiri A; Alswaid A; Eyiad W; Al Mutairi F; Ababneh F; Alfadhel M; Alfares A
    Am J Med Genet A; 2022 Jan; 188(1):83-88. PubMed ID: 34515413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Misattributed parentage as an unanticipated finding during exome/genome sequencing: current clinical laboratory practices and an opportunity for standardization.
    Eno C; Bayrak-Toydemir P; Bean L; Braxton A; Chao EC; El-Khechen D; Esplin ED; Friedman B; Hagman KDF; Hambuch T; Hernandez A; Juusola J; Londre G; Machado J; Mao R; Mighion L; Rehm HL; Ward P; Deignan JL
    Genet Med; 2019 Apr; 21(4):861-866. PubMed ID: 30214068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient re-contact after revision of genomic test results: points to consider-a statement of the American College of Medical Genetics and Genomics (ACMG).
    David KL; Best RG; Brenman LM; Bush L; Deignan JL; Flannery D; Hoffman JD; Holm I; Miller DT; O'Leary J; Pyeritz RE;
    Genet Med; 2019 Apr; 21(4):769-771. PubMed ID: 30578420
    [No Abstract]   [Full Text] [Related]  

  • 19. Actionable secondary findings in the 73 ACMG-recommended genes in 1559 Thai exomes.
    Chetruengchai W; Shotelersuk V
    J Hum Genet; 2022 Mar; 67(3):137-142. PubMed ID: 34621001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Points to consider in the detection of germline structural variants using next-generation sequencing: A statement of the American College of Medical Genetics and Genomics (ACMG).
    Raca G; Astbury C; Behlmann A; De Castro MJ; Hickey SE; Karaca E; Lowther C; Riggs ER; Seifert BA; Thorland EC; Deignan JL;
    Genet Med; 2023 Feb; 25(2):100316. PubMed ID: 36507974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.